SEMINAR: Plant-made biopharmaceuticals
Mar 22, 2017
from 12:00 PM to 01:30 PM
|Where||Vogt Bldg., RM 311|
|Contact Name||nancy hansford|
|Add event to calendar||vCal|
Abstract: Plants offer several benefits as a recombinant protein factory. These include the eukaryotic protein biosynthesis machinery and the potential for low-cost and large-scale production. Recent advent of transient overexpression vectors based on plant viruses has opened a new avenue for the development of novel biopharmaceuticals, whereby candidate proteins can be rapidly designed, screened and developed for preclinical and clinical testing as well as commercialization. Several plan-made vaccines and biotherapeutics against human viral pathogens are under clinical development. We are currently developing a bacterial toxin-derived immunomodulatory protein for Inflammatory Bowel Disease therapy and a lectin-human immunoglobulin fusion protein for HIV, HCV and cancer treatment.
Speaker: Dr. Nobuyuki Matoba received his Ph.D. degree in Applied Life Science from Kyoto University, Japan. He is an Associate Professor (with tenure) of Pharmacology & Toxicology and a Principal Investigator of Center for Predicitive Medicine and James Graham Brown Cancer Center at University of Louisville School of Medicine. Before joining the UofL faculty, he had been a Japan Society for Promothion of Science (JSPS) Research Fellow, a JSPS Postdoctoral Fellow for Research Abroad, and a Research Assistant Professor at Arizona State University Biodesign Institute. He currently serves on the editorial board of the journal Scientific Reports. Dr. Matoba's research is focused on the development of plant-made protein pharmaceuticals. In particular, he is interested in engineering subunit vaccines and biotherapeutics against mucosal diseases.